> GlaxoSmithKline and Oxford University have announced plans for a major cancer research center in India. The new center will make more experimental drugs available to the subcontinent and make the country a far more important player in the oncology field. Report
> With fears of bird-flu on the rise, companies like Microsoft have been pondering how they will respond to a potential pandemic. Mass telecommuting is one option. Report
> The FDA has asked for more information from Roche on the deaths of 12 children taking Tamiflu. Report
> Switzerland's Actelion has struck a deal to acquire full control of the drug Zavesca from Belgium's UCB. The deal replaces an earlier pact with Celltech, which UCB had acquired. The drug is used to treat mild to moderate Gaucher type 1 disease. Release
> As expected, an FDA expert panel is recommending that Novartis provide more data on the safety and efficacy of Certican for heart transplant patients. Release
> Human Genome Sciences said that a Phase II trial for LymphoStat-B in patients with rheumatoid arthritis met primary endpoints for safety, tolerability and efficacy. Release
> YM BioSciences' majority-owned subsidiary, CIMYM, has partnered with Innogene Kalbiotech of Singapore to expand the development program for its humanized, EGF receptor-targeting monoclonal antibody, nimotuzumab. Release
> Iconix Pharmaceuticals of Mountain View, CA, has inked a research and license agreement with Eli Lilly. Release
> Human Pheromone Sciences of San Jose has terminated a deal to sell unregistered shares to Rubinson & Associates. Release
> Biomira says that a Phase II study of BLP25 Liposome Vaccine indicates no safety concerns. Release
And Finally... China will vaccinate all of the 5.2 billion chicken, geese and ducks in the country to guard against bird flu. Article